目的研究胰高血糖素样肽素-1(glucogon like pep tide-1,GLP-1)对晚期糖基化终产物(advanced glycation end products,AGEs)诱导H9C2心肌细胞凋亡的保护作用机制。方法体外培养H9C2细胞,实验分为4组:正常对照组、100 mg·L^(-1)AGE...目的研究胰高血糖素样肽素-1(glucogon like pep tide-1,GLP-1)对晚期糖基化终产物(advanced glycation end products,AGEs)诱导H9C2心肌细胞凋亡的保护作用机制。方法体外培养H9C2细胞,实验分为4组:正常对照组、100 mg·L^(-1)AGEs试验组、AGEs(100 mg·L^(-1))+GLP-1(10 nmol·L^(-1))组、AGEs(100 mg·L^(-1))+NAC(5 mmol·L^(-1))组,处理24 h。通过CCK-8比色法检测细胞存活率,相差显微镜观察细胞形态,双氯荧光素(DCFH-DA)染色荧光显微镜摄片观察细胞内活性氧(ROS)水平;RT-PCR法测定Bax、Bcl-2 mRNA基因的表达;运用Hoechst 33258检测试剂盒及流式细胞术检测心肌细胞的凋亡率,Western blot检测凋亡相关蛋白Bax、Bcl-2的表达量。结果与正常组相比,100 mg·L^(-1)AGEs组降低H9C2细胞生存率,活性氧(ROS)生成量增加;与AGEs组相比,AGEs+GLP-1组细胞生成率提高,活性氧(ROS)生成量减少。与正常组相比,AGEs组促凋亡蛋白Bax表达增加,抑制凋亡蛋白Bcl-2减少,细胞凋亡率升高;AGEs+GLP-1组较AGEs组下调促凋亡蛋白Bax,上调凋亡抑制蛋白Bcl-2,细胞凋亡率减少。结论 GLP-1对AGEs诱导的心肌细胞凋亡具有保护作用,其保护机制与减少活性氧(ROS)有关。展开更多
This study aimed to investigate the protective effects of astragaloside IV(AS IV) on lipopolysaccharide(LPS)-induced injury in H9C2 cardiomyocytes. H9C2 Cardiomyocytes were cultured with LPS(10 μg·mL-1) for 4 h ...This study aimed to investigate the protective effects of astragaloside IV(AS IV) on lipopolysaccharide(LPS)-induced injury in H9C2 cardiomyocytes. H9C2 Cardiomyocytes were cultured with LPS(10 μg·mL-1) for 4 h and treated with AS IV at 50, 100, and 150 μmol·L-1 for various durations. Cell viability was determined by MTT. The content of released TNF-α and IL-6 from cardiomyocytes were evaluated by enzyme-linked immunosorbent assay(ELISA). The levels of superoxidase dismutase(SOD), malondialdehyde(MDA), lactate dehydrogenase(LDH), and creatine phosphate kinase(CK) were measured by using commercial available kits. The mR NA and protein expression levels of NF-κB p65 were measured by RT-PCR and Western blotting, respectively. And the NF-κB p65 activity was measured by ELISA. Our results demonstrated that AS IV at 50, 100, and 150 μmol·L-1 markedly inhibited the release of TNF-α and IL-6 and decreased NF-κB expression, compared with the model group. Moreover, the improved SOD activity and decreased MDA, LDH and CK levels were detected after AS IV treatment. In summary, AS IV could increase the activities of antioxidant enzymes, inhibite lipid peroxidation, and down-regulate the inflammatory mediators involved in the inflammatory responses. These results demonstrated that AS IV could prevent LPS-induced injury in cardiomyocytes.展开更多
基金supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)Nanjing University of Chinese Medicine Natural Science Foundation for the Youth(No.12XZR06)+1 种基金Anhui Province Natural Science Foundation(No.1408085MH146)Anhui University of Chinese Medicine Natural Science Foundation(No.2015qn023)
文摘This study aimed to investigate the protective effects of astragaloside IV(AS IV) on lipopolysaccharide(LPS)-induced injury in H9C2 cardiomyocytes. H9C2 Cardiomyocytes were cultured with LPS(10 μg·mL-1) for 4 h and treated with AS IV at 50, 100, and 150 μmol·L-1 for various durations. Cell viability was determined by MTT. The content of released TNF-α and IL-6 from cardiomyocytes were evaluated by enzyme-linked immunosorbent assay(ELISA). The levels of superoxidase dismutase(SOD), malondialdehyde(MDA), lactate dehydrogenase(LDH), and creatine phosphate kinase(CK) were measured by using commercial available kits. The mR NA and protein expression levels of NF-κB p65 were measured by RT-PCR and Western blotting, respectively. And the NF-κB p65 activity was measured by ELISA. Our results demonstrated that AS IV at 50, 100, and 150 μmol·L-1 markedly inhibited the release of TNF-α and IL-6 and decreased NF-κB expression, compared with the model group. Moreover, the improved SOD activity and decreased MDA, LDH and CK levels were detected after AS IV treatment. In summary, AS IV could increase the activities of antioxidant enzymes, inhibite lipid peroxidation, and down-regulate the inflammatory mediators involved in the inflammatory responses. These results demonstrated that AS IV could prevent LPS-induced injury in cardiomyocytes.
